Journal of Biomedical Science · 2023 · 12 citations · 39 references
Life SciencesImmunologyInfectious DiseasesImmunology Of Infectious DiseasesMolecular VirologyVirologyAntibody CharacterizationAntibody DiscoveryAntibody Library ConstructionAntiviral ImmunityViral InfectionsAntibodiesAntibody-mediated Viral NeutralizationAntibody-mediated Virus NeutralizationB Cell CloningNeutralizationSars-cov-2 InfectionSingle-cell CloningVaccination-induced Antibody Responses
Abstract Background The COVID-19 pandemic continues to pose a significant worldwide threat to human health, as emerging SARS-CoV-2 Omicron variants exhibit resistance to therapeutic antibodies and the ability to evade vaccination-induced antibodies. Here, we aimed to identify human antibodies (hAbs) from convalescent patients that are potent and broadly neutralizing toward Omicron sublineages. Methods Using a single B-cell cloning approach, we isolated BA.5 specific human antibodies. We further examined the neutralizing activities of the most promising neutralizing hAbs toward different variants of concern (VOCs) with pseudotyped virus. Results Sixteen hAbs showed strong neutralizing activities against Omicron BA.5 with low IC 50 values (IC 50 < 20 ng/mL). Among four of the most promising neutralizing hAbs (RBD-hAb-B22, -B23, -B25 and -B34), RBD-hAb-B22 exhibited the most potent and broad neutralization profiles across Omicron subvariant pseudoviruses, with low IC 50 values (7.7–41.6 ng/mL) and a low PRNT 50 value (3.8 ng/mL) in plaque assays with authentic BA.5. It also showed potent therapeutic effects in BA.5-infected K18-hACE2 mice. Conclusions Thus, our efficient screening of BA.5-specific neutralizing hAbs from breakthrough infectious convalescent donors successfully yielded hAbs with potent therapeutic potential against multiple SARS-CoV-2 variants.
39
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Renhong Yan, Yuanyuan Zhang, Yaning Li et al. · Science · 2020 · 5.6K citations · Full text
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Dora Pinto, Young‐Jun Park, Martina Beltramello et al. · Nature · 2020 · 2.2K citations · Full text
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Christopher O. Barnes, Claudia A. Jette, Morgan E. Abernathy et al. · Nature · 2020 · 1.9K citations · Full text
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Zijun Wang, Fabian Schmidt, Yiska Weisblum et al. · Nature · 2021 · 1.5K citations · Full text
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Lihong Liu, Sho Iketani, Yicheng Guo et al. · Nature · 2021 · 1.4K citations · Full text